Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL
- Share this website :
Resource Centre for HCPs
Recent advances
Chronic Myeloid Leukaemia (CML)
Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities
Development of asciminib, a novel allosteric inhibitor of BCR-ABL1
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs
Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
Molecular monitoring in CML: how deep? How often? How should it influence therapy?
Useful links
AML Hub
MPN Hub
MDS Hub
European LeukemiaNet
American Society of Haematology
The European Haematology Association (EHA)
British Society of Haematology (BSH)
National Comprehensive Cancer Network (NCCN) ®
The Hong Kong Society of Haematology
Singapore Society of Haematology
Malaysian Society of Haematology
The Hematology Society of Taiwan
The Thai Society of Hematology
